> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Commentary Questions FDA's Drug Innovation Policies
- URL: https://www.fdaweb.com/commentary-questions-fdas-drug-innovation-policies/
- Published: 2026-07-31T12:00:00.000Z
- Updated: 2026-09-14T13:44:15.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5161560

A new Harvard Law School [legal commentary post](https://petrieflom.law.harvard.edu/2026/07/31/innovation-politics-at-the-fda/?ref=fdaweb.com) argues that decades of policies designed to accelerate pharmaceutical innovation may have instead encouraged investment in drugs that offer limited clinical benefit while leaving important public health needs underserved.

Legal scholars **Daniel Aaron** and **Avery Emery** contend that any debate over whether FDA is "pro-innovation" depends largely on how innovation is defined. While the pharmaceutical industry often measures innovation by the number of new drugs reaching the market, the authors argue that a better measure is patient value, including whether a therapy delivers meaningful clinical benefits, addresses unmet medical needs, or represents a first-in-class advance.

The authors point to the FDA's accelerated approval pathway as an example of the tension. They note that oncology accounts for roughly 60% of accelerated approvals and argue that many newly approved cancer drugs provide only modest survival gains despite carrying high launch prices. They contend that lower regulatory barriers and favorable reimbursement policies have encouraged companies to concentrate development in oncology rather than areas such as antibiotics, vaccines and cancer prevention, where they say important public health needs remain inadequately addressed.

The commentary also cites several drugs approved through expedited pathways — including Alzheimer's disease therapies Aduhelm and Leqembi and the preterm birth drug Makena — as examples that have fueled concerns about reduced evidentiary standards. The authors stress that FDA review remains robust in many areas but argue that the expansion of expedited programs has altered investment incentives across the pharmaceutical industry.

Looking ahead, Aaron and Emery argue that redefining innovation around patient benefit rather than development volume would help shift regulatory policy toward higher-value therapies. They also call for greater collaboration among public health experts, researchers, patient advocates and other stakeholders to challenge what they describe as industry-driven narratives surrounding pharmaceutical innovation.